A

Amgen

Makes biotech medicines for serious illnesses

Principal Solution Architect

Full-TimeUpdated on 10/24/2026
No salary listed
Expert
Bachelor's, Master's
Hyderabad, Telangana, India
In Person
Data & AnalyticsData Engineering

About the job

Requirements
  • A Master’s degree with 12–15 years of experience in Computer Science, IT, or a related field, or a Bachelor’s degree with 14–17 years of experience in those fields.
  • At least 8 years of hands-on experience in data integrations, data management, and business intelligence technology.
  • Strong experience with one or more data management tools, such as AWS data lake, Snowflake, or Azure Data Fabric.
  • Expert-level proficiency with Databricks and experience optimizing data pipelines and workflows in Databricks environments.
  • Strong experience with Python, PySpark, and SQL for building scalable data workflows and pipelines.
  • Experience with Apache Spark, Delta Lake, and other relevant technologies for large-scale data processing.
  • Familiarity with business intelligence tools, including Tableau and Power BI.
  • Ability to enhance cost-efficiency, scalability, and performance for data solutions.
  • Analytical and problem-solving skills to address complex data solutions.
  • Analytical and troubleshooting skills.
  • Verbal and written communication skills.
  • Ability to work effectively with global, virtual teams.
  • Initiative and self-motivation.
  • Ability to manage multiple priorities successfully.
  • Team orientation with a focus on achieving team goals.
  • Presentation and public speaking skills.
Responsibilities
  • Implement and manage large-scale data analytic solutions for Amgen functional groups in alignment with Amgen’s data strategy.
  • Collaborate with Business, Program Management, Data Engineering, and Analytic Engineering teams to deliver data solutions.
  • Design, develop, optimize, deliver, and support data solutions on AWS and Databricks architecture.
  • Use cloud platforms, with AWS preferred, to build scalable and efficient data solutions.
  • Provide expert guidance and mentorship to team members, fostering innovation and best practices.
  • Experiment hands-on with new data-related technologies.
  • Define guidelines, standards, strategies, security policies, and change management policies to support the Enterprise Data Platform.
  • Collaborate and align with EARB, Cloud Infrastructure, Security, and other technology leaders on Enterprise Data Architecture changes.
  • Work with project and application groups to drive growth of the Enterprise Data Platform and lead demonstrations at roadmap sessions.
  • Manage the Enterprise Data Platform in the AWS environment to ensure cost-effective service delivery and achievement of business service-level targets for uptime, performance, and capacity.
  • Ensure scalability, reliability, and performance of data platforms through architecture best practices, cloud resource optimization, and system tuning.
  • Collaborate with RunOps engineers to increase the speed and automation of production changes.
  • Maintain knowledge of market trends and developments in data integration, data management, and analytics software and tools.
  • Work as part of a team in a SAFe Agile/Scrum model.
Desired Qualifications
  • Experience in life sciences, technology, or consultative solution architecture roles.
  • Experience with agile development methodologies such as Scaled Agile.
  • AWS Certified Data Engineer certification.
  • Databricks certification.

About the company

Amgen develops and makes biologic medicines, which are drugs built from proteins and antibodies grown in living cells, for serious conditions such as heart disease, cancer, and bone loss. Its anemia drug Epogen, approved in 1989, became one of the biotechnology industry's first blockbuster medicines. Amgen grows these drugs in large tanks called bioreactors, and its products include the cholesterol drug Repatha, the bone-building drug Evenity, and the severe asthma drug Tezspire. It earns money by selling these medicines, mostly through large drug wholesalers that supply hospitals and pharmacies. Amgen was founded in 1980 and is based in Thousand Oaks, California.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Get referred to Amgen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Growth is broad-based: 22 products grew at least 10%, lifting June 2026 quarter revenue 10% to $10.1 billion.
  • Stock grants gained value: Amgen shares rose 27% from January to October 9, 2026, versus 10% for rival Eli Lilly.
  • Many U.S. roles are remote: 145 of Amgen's 615 U.S. job openings in October 2026 were fully remote.

What critics are saying

  • Its 2025 best seller is shrinking: cheaper copies cut bone drug Prolia's sales 32% in the June 2026 quarter.
  • MariTide, Amgen's obesity bet, faces a giant: Lilly's Mounjaro and Zepbound outsold all of Amgen in the June 2026 quarter.
  • Most tech openings are in India: 156 of Amgen's 210 information systems jobs in October 2026 were in Hyderabad.

What makes Amgen unique

  • It copies rivals' blockbusters too: Pavblu, its version of Regeneron's eye drug Eylea, sold $700 million in 2025.
  • Amgen hunts drug targets in a nation's DNA: its Icelandic unit deCODE has genetic data on two-thirds of Iceland's adults.
  • Amgen opened a U.S. cancer-drug class: Blincyto, approved in 2014, was the first to tether immune cells to cancer.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Professional Development Budget
  • Conference Attendance Budget

Company News

Yahoo Finance
Oct 25th, 2026
Amgen vs Gilead: Which biotech dividend stock is the better buy, with yields of 2.2% and 2.1%?

Amgen and Gilead Sciences, two of the few big biotech companies that pay dividends, suit different kinds of income investors, according to a comparison by The Motley Fool's Keith Speights. Amgen offers a forward dividend yield above 2.2%, against slightly below 2.1% for Gilead. Gilead has the lower payout ratio, at 43.5% versus 60.9%, and the cheaper valuation: 15.6 times forward earnings against 16.7. Amgen's product sales grew 9% year over year in its latest quarter, against 8% for Gilead. It has 17 drugs on track to be blockbusters this year, versus eight for Gilead, and 29 late-stage programs. Speights favours Amgen for yield and growth, and Gilead for safety and value.

Yahoo Finance
Oct 24th, 2026
Amgen vs Johnson & Johnson: cheaper Amgen edges J&J's $94.2B revenue giant on valuation

A Motley Fool comparison of Amgen and Johnson & Johnson (J&J) favours Amgen, mainly on price. Amgen's forward price-to-earnings ratio is 19.4x, against 24.1x for J&J. In 2025, Amgen's revenue rose about 10% to $36.7 billion, with net income of $7.7 billion. J&J's revenue grew 6% to $94.2 billion, with net income of $26.8 billion and free cash flow of $19.7 billion. Amgen carries far more debt: its debt-to-equity ratio is nearly 6.3x, against about 0.6x for J&J. Three wholesalers account for 77% of its gross revenues. Amgen also struck a deal with the US government that exempts it from pharmaceutical tariffs for three years in return for price cuts on two drugs. J&J expects revenue of $101 billion this fiscal year, and Amgen expects about $37.8 billion.

Yahoo Finance
Oct 22nd, 2026
Eli Lilly vs Amgen: $65.2B revenue and 45% growth against a cheaper stock for 2026

Eli Lilly is growing far faster than Amgen, but investors pay a steep premium for it. The article's author favours Lilly for long-term investors in 2026. Lilly's FY 2025 revenue rose 45% to about $65.2 billion, with net income of $20.6 billion and a 32% net margin. Amgen's revenue grew about 10% to $36.7 billion, with net income of $7.7 billion and a 21% margin. Lilly trades at a forward P/E of 38.3x against Amgen's 19.4x. Its debt-to-equity ratio is about 1.6x, compared with nearly 6.3x for Amgen. Lilly's growth rests on its GLP-1 drugs Zepbound and Mounjaro. The article projects 2026 revenue of $88.7 billion, against about $37.8 billion for Amgen.

Yahoo Finance
Oct 21st, 2026
Amgen's focus shifts to six growth drivers and MariTide as rare disease sales hit $1.6B

Amgen now frames its story around six key growth drivers, which grew 26% from a year earlier in fiscal Q2 2026 and made up nearly 70% of product sales. Rare disease, once reported on its own, is one of the six. The rare disease portfolio grew 21% to $1.6 billion, about 16% of quarterly revenue. Total revenue rose 9.5%, and management raised its 2026 revenue guidance to between $38.2 billion and $39.4 billion. Management also highlighted MariTide, an obesity drug in Phase III trials. Amgen wants it to be the first monthly or less frequent obesity therapy and is already scaling up manufacturing. One risk sits in rare disease. On September 1, 2026, Britain's medicines regulator suspended Tavneos for new patients, citing an unreliable main study. The drug made $119 million in fiscal Q1 2026. Amgen's next report is expected around November 3, 2026.

Yahoo Finance
Oct 20th, 2026
Johnson & Johnson and Amgen beat the market in 2026, but can the dividend stocks keep going?

Johnson & Johnson and Amgen, two dividend stocks that have beaten the broader market this year, could suit investors bracing for a possible crash. J&J's latest quarter beat expectations, and it slightly raised its 2026 guidance. But its medtech unit is struggling, as demand for the Impella heart pump has fallen amid safety questions and a US Class 1 recall. Long-term, it has new drugs, a robotic surgery system approved in the US, and a proposed $5.5 billion talc settlement. It is a Dividend King with 64 straight years of payout increases. Amgen's second-quarter revenue rose 10% to $10.1 billion, despite pressure on Tavneos and falling denosumab sales. It has raised payouts 152% over a decade and offers a 2.3% forward yield, against 1.1% for the S&P 500.